Abstracts tagged "interstitial lung disease"

Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Karina Bonfiglioli¹, Márcio Sawamura ², Renato Nakagawa ³, Fábio Arimura ³, Diana Rangel ³, Cleonice Bueno ⁴, Ana Cristina de Medeiros Ribeiro ¹, Carlos Carvalho ³, Eloisa Bonfa ⁵, Ronaldo Kairalla ³ and Leticia Kawano-Dourado ⁶, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, ³Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁶University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
Abstract Number: 740 • 2019 ACR/ARP Annual Meeting
Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease
Magdalena Benad ¹, Dirk Koschel ¹, Kristine Herrmann ¹, Kristin Wiefel ¹, Alexander Kleymann ¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: Interstitial lung disease (ILD) is a common and life-threatening organ manifestation of patients with various connective tissue diseases (CTDs), and with systemic sclerosis and…
Abstract Number: 1830 • 2019 ACR/ARP Annual Meeting
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth Volkmann¹, Virginia Steen ², Ning Li ³, Michael Roth ⁴, Philip Clements ³, Dinesh Khanna ⁵, Daniel Furst ⁶, Shervin Assassi ⁷, Grace Kim ³, Jonathan Goldin ³, Robert Elashoff ³ and Donald Tashkin ³, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²Georgetown University, Washington, D.C., USA, Georgetown, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁶University of California, Los Angeles, CA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: Observational studies have demonstrated that African American (AA) patients with systemic sclerosis (SSc) have a more unfavorable prognosis compared with non-AA. However, no studies…
Abstract Number: 2360 • 2019 ACR/ARP Annual Meeting
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Silvana Saavedra¹, Karen Vergara ², Claudia Hernandez ², Pedro Zamorano ², Annelise Goecke ², Luis Toro ² and FELIPE REYES ¹, ¹HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Chile, ²HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Region Metropolitana, Chile
Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA) that may be related to the inflammatory process itself, to infectious…
Abstract Number: 796 • 2019 ACR/ARP Annual Meeting
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs ², Kathryn Torok ³, Maria José Santos ⁴, Ozgur Kasapcopur ⁵, Amra Adrovic ⁶, Valda Stanevicha ⁷, Flavio Sztajnbok ⁸, Maria Teresa Terreri ⁹, Ekaterina Alexeeva ¹⁰, Jordi Antón ¹¹, Maria Katsicas ¹², Vanessa Smith ¹³, Tadej Avcin ¹⁴, Rolando Cimaz ¹⁵, Mikhail Kostik ¹⁶, Thomas Lehman ¹⁷, Walter Sifuentes-Giraldo ¹⁸, Simone Appenzeller ¹⁹, Mahesh Janarthanan ²⁰, Monika Moll ²¹, Dana Nemcova ²², Dieneke Schonenberg ²³, Christina Battagliotti ²⁴, Lillemor Berntson ²⁵, Blanca Bica ²⁶, Juergen Brunner ²⁷, Patricia Costa Reis ²⁸, Despina Eleftheriou ²⁹, Liora Harel ³⁰, Gerd Horneff ³¹, Tilmann Kallinich ³², Dragana Lazarevic ³³, Kirsten Minden ³⁴, Susan Nielsen ³⁵, Farzana Nuruzzaman ³⁶, Anjali Patwardhan ³⁷, Yosef Uziel ³⁸ and Nicola Helmus ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ²Asklepios Klinik Nord - Heidberg, Hamburg, Germany, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁵Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁰National Medical Research Center of Children`s Health, Moscow, Russia, ¹¹Hospital Sant Joan de Déu, Barcelona, Spain, ¹²Hospital de Pediatria, Buenos Aires, Argentina, ¹³Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ¹⁴Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁵University Hospital Meyer, Florence, Italy, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁷Hospital for Special Surgery, New York, ¹⁸Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁹UNICAMP Universidade Estadual de Campinas, Sao Paulo, Brazil, ²⁰Sri Ramachandra University, Chennai, India, ²¹University of Tuebingen, Tuebingen, Germany, ²²General University Hospital, Prague, Czech Republic, ²³Amsterdam UMC, Amsterdam, Netherlands, ²⁴Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁵Uppsala University Hospital, Uppsala, Sweden, ²⁶Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁷Tirol Kliniken, Innsbruck, Austria, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹Great Ormond Street Hospital, London, United Kingdom, ³⁰Tel Aviv University, Tel Aviv, Israel, ³¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³²Charite, Berlin, Germany, ³³KC Niš, Niš, Serbia, ³⁴German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ³⁵Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhavn, Denmark, ³⁶Stony Brook Children's Hospital, Stony Brook, NY, ³⁷University of Missouri, Columbia, ³⁸Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence in around 3 in a million children[1]. Pulmonary involvement in jSSc occurs in approximately 40…
Abstract Number: 1831 • 2019 ACR/ARP Annual Meeting
Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
Sarah French¹, Kim Taylor ¹, Stephanie Rush ² and Francesco Boin ¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA
Background/Purpose: Pulmonary disease is a leading cause of mortality in scleroderma (SSc). Previous studies indicate that the coexistence of pulmonary hypertension (PH) and interstitial lung…
Abstract Number: 2603 • 2019 ACR/ARP Annual Meeting
Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Anna-Maria Hoffmann-Vold¹, Yannick Allanore ², Margarida Alves ³, Nicole Graf ⁴, Paolo Airò ⁵, Lidia P. Ananyeva ⁶, László Czirják ⁷, Serena Guiducci ⁸, Eric Hachulla ⁹, Mengtao Li ¹⁰, Carina Mihai ¹¹, Gabriela Riemekasten ¹², Petros Sfikakis ¹³, Gabriele Valentini ¹⁴, Otylia Kowal-Bielecka ¹⁵ and Oliver Distler ¹⁶, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland, Winterthur, Switzerland, ⁵UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy, ⁶VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁸Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁹Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ¹⁰Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic), ¹¹Dept. of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Dept. of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, ¹³Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁴Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ¹⁵Dept. of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, Bialystok, Poland, ¹⁶Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is heterogeneous; some patients may experience rapid decline in lung function, while others have relatively…
Abstract Number: 843 • 2019 ACR/ARP Annual Meeting
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Michail Alevizos¹, Sonye Danoff ², Dimitrios Pappas ¹, David Lederer ³, Cheilonda Johnson ⁴, Elana Bernstein ⁵, Joan Bathon ⁵ and Jon Giles ⁵, ¹Division of Rheumatology, Columbia University, New York, ²Division of Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, ³Division of Pulmonary & Critical Care Medicine, Columbia University, New York, ⁴Division of Pulmonary & Critical Care Medicine, University of Pennsylvania, Philadelphia, ⁵Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: Risk factors for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a significant cause of morbidity and mortality, are poorly understood. RA-ILD detection is limited by…
Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Kristin Highland¹, Oliver Distler ², Masataka Kuwana ³, Yannick Allanore ⁴, Shervin Assassi ⁵, Arata Azuma ⁶, Arnaud Bourdin ⁷, Christopher Denton ⁸, Jörg Distler ⁹, Anna Maria Hoffmann-Vold ¹⁰, Dinesh Khanna ¹¹, Maureen Mayes ⁵, Ganesh Raghu ¹², Madelon Vonk ¹³, Martina Gahlemann ¹⁴, Mannaig Girard ¹⁵, Susanne Stowasser ¹⁶, Donald Zoz ¹⁷, Aryeh Fischer ¹⁸ and Toby Maher ¹⁹, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁷PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, ⁸University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²University of Washington, Seattle, USA, Seattle, ¹³Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ¹⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹⁵Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ¹⁸University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ¹⁹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…
Abstract Number: 2606 • 2019 ACR/ARP Annual Meeting
Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation
Jacopo Ciaffi¹, Nina van Leeuwen ², Maaike Boonstra ², Lucia Kroft ³, Anne Schouffoer ³, Maarten Ninaber ², Thomas Huizinga ² and Jeska de Vries-Bouwstra ², ¹Leiden University Medical Center, Bologna, Emilia-Romagna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Three trials demonstrated the overall superiority of autologous hematopoietic stem cell transplantation (HSCT) compared to pulsed cyclophosphamide (CYC) in SSc. An improvement in forced…
Abstract Number: 874 • 2019 ACR/ARP Annual Meeting
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Iazsmin Ventura¹, Anisha Dua ², Ayodeji Adegunsoye ³, Mary Strek ³, James Curran ¹, Alexandra Weiss ¹ and Jonathan Chung ¹, ¹University of Chicago, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Chicago, Department of Pulmonary and Critical Care, Chicago
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…
Abstract Number: 1834 • 2019 ACR/ARP Annual Meeting
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Ning Li ², Elizabeth Volkmann ³, Maureen Mayes ¹, Jun Ying ⁴, Michael Roth ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Jonathan Goldin ², Robert Elashoff ² and Donald Tashkin ², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological…
Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Cosimo Bruni¹, Mariaelena Occhipinti ², Gianna Camiciottoli ³, Maurizio Bartolucci ⁴, Michael Pienn ⁵, Gemma Lepri ¹, Alessio Fabbrizzi ³, Alessandra Tottoli ¹, Giulia Ciardi ³, Dilia Giuggioli ⁶, Giovanna Cuomo ⁷, Francesco Masini ⁷, Andrea Olschewski ⁵, Federico Lavorini ³, Stefano Colagrande ⁸ and Marco Matucci-Cerinic ⁹, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Dept. Experimental and Clinical Medicine, Div. Pneumology and Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ³Dept. Experimental and Clinical Medicine, Div. Pneumology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁴Dept. of Services, Div. Emergency-Urgency Radiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ⁵Ludwig Boltzmann Institute for Lung Vascular Research, Institute of Physiology, Medical University of Graz, Graz, Austria, ⁶Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy, ⁸Dept. Experimental and Clinical Medicine, Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…
Abstract Number: 962 • 2019 ACR/ARP Annual Meeting
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Erin Wilfong¹, Jennifer Young-Glazer ², Elise Rizzi ³, Rosemarie Dudenhofer ², Leslie Crofford ¹ and Peggy Kendall ², ¹Vanderbilt University, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville
Background/Purpose: Systemic sclerosis (SSc) is a severe systemic disease characterized by fibrosis of the skin and visceral organs. While protein biomarkers of lung damage, e.g.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].